Sienna Biopharmaceuticals Inc. (SNNA) and Its Peers Financial Results Comparison

As Biotechnology company, Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) is competing with its competitors based on the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Insider and Institutional Ownership

Sienna Biopharmaceuticals Inc. has 32.3% of its shares held by institutional investors & an average of 52.39% institutional ownership for its rivals. 4.3% of Sienna Biopharmaceuticals Inc. shares are held by company insiders. Comparatively, 8.89% of all Biotechnology companies shares are held by company insiders.


Table 1 has Sienna Biopharmaceuticals Inc. and its rivals’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Sienna Biopharmaceuticals Inc. 0.00% -97.50% -50.20%
Industry Average 468.58% 80.16% 25.47%

Earnings and Valuation

The following data compares Sienna Biopharmaceuticals Inc. and its rivals’ valuation, gross revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Sienna Biopharmaceuticals Inc. 73.47M N/A 0.00
Industry Average 14.75M 3.15M 89.01

Analyst Ratings

Table 3 shows summary of recent ratings for Sienna Biopharmaceuticals Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sienna Biopharmaceuticals Inc. 0 0 1 3.00
Industry Average 1.22 1.87 2.93 2.79

With average target price of $17, Sienna Biopharmaceuticals Inc. has a potential upside of 665.77%. As a group, Biotechnology companies have a potential upside of 126.19%. Given Sienna Biopharmaceuticals Inc.’s rivals higher probable upside, analysts plainly believe Sienna Biopharmaceuticals Inc. has less favorable growth aspects than its rivals.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Sienna Biopharmaceuticals Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sienna Biopharmaceuticals Inc. 13.44% 7.09% -71.81% -83.09% -82.01% 23.71%
Industry Average 7.88% 20.03% 31.47% 42.06% 73.21% 38.48%

For the past year Sienna Biopharmaceuticals Inc. was less bullish than its competitors.


The Current Ratio and a Quick Ratio of Sienna Biopharmaceuticals Inc. are 4.9 and 4.9. Competitively, Sienna Biopharmaceuticals Inc.’s rivals have 7.48 and 7.37 for Current and Quick Ratio. Sienna Biopharmaceuticals Inc.’s peers have better ability to pay short and long-term obligations than Sienna Biopharmaceuticals Inc.


Sienna Biopharmaceuticals Inc. does not pay a dividend.


Sienna Biopharmaceuticals Inc.’s peers beat Sienna Biopharmaceuticals Inc. on 3 of the 4 factors.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.